Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
The mammalian target of rapamycin plays a critical role in cell differentiation, migration, and survival. Inhibitors of rapamycin, such as sirolimus or everolimus, have demonstrated anti-inflammatory, antifibrotic, antitumor, and antifungal properties that underscore the involvement of rapamycin signalling in various cellular functions. Activation of rapamycin phosphorylates p70 ribosomal S6kinase (p70S6K) and eukaryotic initiation factor-4E (4E-BP1), leading to cell hypertrophy, macrophage and T cell proliferation, and infiltration. Recently, rapamycin inhibitors have been applied in anticancer therapy 3, preventing restenosis of coronary arteries after angioplasty, and in clinical trials and research on the tuberous sclerosis complex and Alzheimer’s disease.
Citation: Stephen C (2015) The Mammalian Target of Rapamycin. J Pharma Care Health Sys 2:132.
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi